Blood Biomarker Signature in Glioma

Status Terminated

Clinical Trial Summary

This is an exploratory, translational and non-interventional clinical study. The aim of this study is to identify a blood biomarker signature for glioma.

Clinical Trial Description

The identification of biomarkers (proteins, peptides and micro RNAs (miRNAs)) in the serum of patients with glioma would be a new, less invasive approach, which could help in the diagnosis of a glioma, and potentially help guide therapeutic decisions. The investigators will investigate the existence of biomarker profiles, which can - distinguish between low and high grade gliomas - correlate with patient outcomes including response to treatment and survival - indicate progression from a low to a high grade glioma. In this study the investigators collect and analyse blood samples taken from patients with suspected newly diagnosed grade II/III glioma or glioblastoma multiforme (GBM). Blood samples will be collected before any surgical intervention (resection or biopsy) and at various follow-up time points until progression or death. Based on the known natural history of gliomas (described above), it is planned to follow patients with grade III/IV tumours, who receive treatment, for up to 3 years and those with grade II-III tumours, (irrespective of treatment) for up to 5 years. Ultimately, the investigators envisage the translation of our observations into the hospital setting to aid the distinction between glioma grade II and grade III/IV. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03698201
Study type	Observational
Source	Cancer Trials Ireland
Contact
Status	Terminated
Phase
Start date	July 2009
Completion date	May 2021

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03796507` - Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation	Early Phase 1
Withdrawn	`NCT04406610` - CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients	Phase 1/Phase 2
Active, not recruiting	`NCT03665545` - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma	Phase 1/Phase 2
Active, not recruiting	`NCT03189420` - Glioma Microenvironment an Exploratory Study
Completed	`NCT03194906` - Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors	Phase 2
Active, not recruiting	`NCT03739372` - Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma	N/A
Completed	`NCT03779230` - Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse	Phase 1/Phase 2
Recruiting	`NCT03728673` - A Study Utilizing Escitalopram in Glioma Patients	Phase 2
Active, not recruiting	`NCT03496181` - Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently
Recruiting	`NCT03180697` - The Efficacy of APT Magnetic Resonance Imaging in Predicting the Efficacy of Bevacizumab in Recurrent Malignant Gliomas	N/A
Recruiting	`NCT03949192` - Efficacy of Kangliuwan for Recurrent Grade IV Glioma
Terminated	`NCT03927274` - Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma	Early Phase 1
Recruiting	`NCT03213002` - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM	Phase 1/Phase 2
Not yet recruiting	`NCT03763396` - Azoles Targeting Recurrent High Grade Gliomas	Early Phase 1
Terminated	`NCT03436433` - Seizure Prophylaxis in Patients With Glioma or Brain Metastasis	Phase 2
Recruiting	`NCT03750890` - Visual Study of Molecular Genotype in Glioma Evolution
Enrolling by invitation	`NCT03102112` - Noninvasively Predicting Gene Status of Glioma	N/A
Active, not recruiting	`NCT03935685` - Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ	Phase 2
Completed	`NCT03834740` - A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection	Early Phase 1
Recruiting	`NCT03849430` - Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients